Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12320460 | 0.75 | LPO (0.40) | KDM4EALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL12277820 | 0.71 | KDM5B (0.46) | POLBKMT2ALMNAMAPTNOTUM | |
| SCHEMBL12277676 | 0.68 | CHKA (0.32) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL12145803 | 0.68 | POLB (0.36) | POLBKDM4EALDH1A1KMT2ALMNA | |
| SCHEMBL32810 | 0.66 | KDM4E (0.46) | KDM4EALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL12277293 | 0.66 | BRD4 (0.36) | KDM4E | |
| SCHEMBL12277680 | 0.66 | HRH4 (0.39) | KMT2AMEN1GAA | |
| SCHEMBL12277792 | 0.66 | RECQL (0.32) | POLBLMNA | |
| SCHEMBL273629 | 0.65 | — | — | |
| SCHEMBL14961826 | 0.64 | POLB (0.47) | POLBKDM4EALDH1A1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-05-07 | — | — | US | disclosed |
| US-20130231335-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8445503-B2 | Inhibitors of polo-like kinase | ELAN PHARMACEUTICALS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| WO-2011079114-A1 | PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | POLB 9/4885KDM4E 1910/4885ALDH1A1 4226/4885 |
| US-20130231335-A1 | INHIBITORS OF POLO-LIKE KINASE | POLK, PLK1, POLR2E | POLB 9/4885KDM4E 1953/4885ALDH1A1 4256/4885 |
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | POLK, PLK1, POLR2E | POLB 9/4885KDM4E 1953/4885ALDH1A1 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.